[Retracted] Targeted Diagnosis, Therapeutic Monitoring, and Assessment of Atherosclerosis Based on Mesoporous Silica Nanoparticles Coated with cRGD-Platelets

Figure 5

Diagnostic and therapeutic evaluation of cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles in vivo. (a) ICP–AES was utilized to determine the enrichment of the cRGD-platelet@MnO/MSN@PPARα/LXRα nanoparticles in the plaque area. (b) HE staining was used to detect the area of vascular lesions affected by cRGD-platelet@MnO/MSN@PPARα/LXRα. (c) TUNEL immunofluorescence assay was used to detect the intimal injury area and plaque area when treated with cRGD-platelet@MnO/MSN@PPARα/LXRα. (d) The level of ROS was detected by DCFH-DA assay. (e) The levels of SOD, MDA, and NOX were evaluated using commercial assay kits. (f) The expression of ABCA1 and LXRα was detected by western blot after treatment with the cRGD-platelet@MnO/MSN@PPARα/LXRα. Data were displayed as the , vs. control. for (b) and (c); for (a), (d), (e), and (f).

(a)

(b)

(c)

(d)

(e)

(f)